ClinicalTrials.gg
Active, not recruitingNCT05290597Updated Mar 5, 2026

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

A Phase 1 interventional study of IBI363 in Solid Malignancies or Lymphomas, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 120 studies in Lymphoma with a site in Australia — 24 open to participants now, 40 under way, 15 of them phase 3. Lymphoma · Australia.

Enrollment
95th of 116
40 · median 132
Started
2022
with 4 others
Phase 1
24 of 120
6 open now
Primary completion
2026-01
later than 5 of 39 live
Registered
93rd of 120
by date

Among the 120 studies in Lymphoma with a site in Australia, this one is the 95th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2022, is one of 24 in phase 1, reaches primary completion later than 5 of the 39 other live ones, and was the 93rd registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

24 of the 120 studies in Lymphoma with a site in Australia are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Lymphoma with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of IBI363 (study drug) in subjects with advanced, refractory solid malignancies or lymphomas.

03

Conditions studied

  • Solid Malignancies or Lymphomas

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, ≥ 18 years
  2. Subjects with a documented (- or cytologically-proven) solid tumor that is locally advanced or ; subjects with documented lymphomas
  3. Subjects with a malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical or non-resectability of the tumor
  4. Subjects who are to or intolerant to existing therapy(ies) known to provide clinical benefit Note: Subjects may have received and failed prior therapy with a /PD-L1 inhibitor and be considered eligible for this trial.
  5. Subjects with measurable or non- according to v1.1 or standard criteria for lymphoma (Lugano 2014)
  6. Subjects, both male and female, who are either not of or who agree to use a highly effective method of during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug
  7. Subjects with the ability to understand and give written for participation in this trial, including all evaluations and procedures as specified by this protocol

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of (WOCBP) or fertile men with WOCBP partner(s), not using and not willing to use a highly effective method of .
  2. Subjects with history of or known active seizure disorder, , spinal cord compression, or carcinomatous meningitis, or new evidence of brain or .
  3. Subjects with:

    • Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to first administration of study drug unless adequately treated and considered by the Investigator to be stable.
    • Active uncontrolled bleeding or a known bleeding diathesis.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    IBI363

    Single arm

    Biological: IBI363

Interventions

  • BiologicalIBI363

    a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.

06

What researchers measure

Primary outcomes

  1. Incidence of serious adverse events (SAEs), treatment-emergent AEs (TEAEs) and immune-related AEs (irAEs)

    An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. A TEAE will be defined as any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered. irAEs will be assessed.

    Time frame: up to 90 days after the last administration

  2. Number of participants with abnormality in vital signs

    Blood pressure, pulse, respiratory rate, and temperature will be assessed.

    Time frame: up to 90 days after the last administration

  3. Number of participants with abnormality in hematology parameters

    Blood samples will be collected to evaluate hemoglobin, mean corpuscular volume (MCV), white blood cell (WBC) count, platelets, 5-part differential white cell count, mean platelet volume and coagulation factors including international normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT)

    Time frame: up to 90 days after the last administration

  4. Number of participants with abnormality in clinical chemistry parameters

    Blood samples will be collected to evaluate sodium, potassium, calcium, magnesium, chloride, glucose, creatinine, urea or blood urea nitrogen (BUN), bicarbonate, amylase, bilirubin, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein, albumin, lactate dehydrogenase and lipase.

    Time frame: up to 90 days after the last administration

  5. Number of participants with abnormality in routine urinalysis parameters

    Urine samples will be collected to evaluate specific gravity, leucocyte esterase, nitrite, blood, bilirubin, protein, glucose, ketones and urobilinogen.

    Time frame: up to 90 days after the last administration

  6. Number of participants with abnormality in ECG parameters

    12-lead ECG will be obtained using an ECG machine. Participants will be in supine or a semi-recumbent position (about 30 degrees of elevation) and rested for approximately 2 minutes before ECGs are recorded.

    Time frame: up to 90 days after the last administration

  7. Number of dose-limiting toxicity (DLT)

    Incidence of dose-limiting toxicity (DLT) events

    Time frame: 28 days during the first 4-week cycle

Secondary outcomes

  1. maximum concentration (Cmax)

    PK parameters to be evaluated for IBI363 including maximum concentration (Cmax) will be determined when appropriate.

    Time frame: Up to 2 years

  2. area under the curve (AUC)

    PK parameters to be evaluated for IBI363 including area under the curve (AUC) will be determined when appropriate.

    Time frame: Up to 2 years

  3. clearance (CL)

    PK parameters to be evaluated for IBI363 including area under the curve (AUC) will be determined when appropriate.

    Time frame: Up to 2 years

  4. half-life (t1/2) of IBI363

    PK parameters to be evaluated for IBI363 including volume of distribution (V) will be determined when appropriate.

    Time frame: Up to 2 years

  5. Objective response rate (ORR)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  6. time to response (TTR)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  7. duration of response (DoR)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  8. disease control rate (DCR)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  9. progression-free survival (PFS)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  10. 6-month and 1-year PFS rate per RECIST v1.1 for subjects with solid tumors, and per Lugano 2014 for subjects with lymphomas

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  11. Overall survival (OS)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: through study completion, an average of 1 year

  12. survival rates (6-month and 1-year)

    To evaluate the preliminary antitumor activity of IBI363

    Time frame: Up to 2 years

  13. The incidence of ADA and NAb of IBI363

    Each subject will be tested for anti-drug (IBI363) antibody (ADA), and ADA-positive serum samples will continue to be tested for neutralizing antibodies (NAb).

    Time frame: Up to 2 years

07

Study locations

4 sites
  • Kate.Wilkinson1@health.nsw.gov.au
    Sydney, New South Wales 2109, Australia
  • Westmead Hospital
    Sydney, New South Wales 2145, Australia
  • Sydney Southwest Private Hospital
    Sydney, New South Wales 2170, Australia
  • Cancer Care Wollongong
    Sydney, New South Wales 2500, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2026, 41 months.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 41 months is close to that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2022
First posted
Mar 22, 2022
StartActual
Aug 22, 2022
Primary completionActual
Jan 28, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05290597
Responsible party
Sponsor
First posted
Mar 22, 2022
Start date
Aug 22, 2022
Primary completion
Jan 28, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Mar 5, 2026

Study contacts

Morteza Aghmesheh
principal investigator · Southern Medical Day Care Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363

Start the discussion